April 26, 2023 - Press Releases
Appointments allow company to consolidate its position as a global leader in the discovery and development of IgE antibody-based therapeutics London, 26 April 2023 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E...
March 3, 2022 - Press Releases
Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital and ALSA Ventures Proceeds from the round will...
February 16, 2021 - Press Releases
Epsilogen is the leading developer of novel IgE antibodies for the treatment of cancer London, 16 February 2021 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, notes that IgEs and...
November 9, 2020 - Press Releases
Expert oncologists will work with Epsilogen to guide the clinical program for its lead candidate, MOv18 IgE London, 9 November 2020 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer...
October 21, 2020 - Press Releases
Company receives second Innovate UK Smart Grant Collaboration with King’s College London London, 21 October 2020 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the...
July 20, 2020 - Press Releases
Company receives grant from Innovate UK Smart Grant London, 20 July 2020 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a £0.5 million grant from the...
June 24, 2020 - Press Releases
Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials Live webinar and conference call on Monday June 29th @ 11am ET / 4pm BST London, June 23, 2020 – Epsilogen, a global leader in the...
April 28, 2020 - Events
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an IgE antibody as a treatment for advanced cancer London, 27 April 2020 – Epsilogen (formerly IGEM...
